Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Phathom Pharmaceuticals (PHAT) Non Operating Income (2022 - 2025)

Historic Non Operating Income for Phathom Pharmaceuticals (PHAT) over the last 4 years, with Q3 2025 value amounting to -$14.7 million.

  • Phathom Pharmaceuticals' Non Operating Income rose 53.45% to -$14.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$61.1 million, marking a year-over-year decrease of 1854.62%. This contributed to the annual value of -$56.9 million for FY2024, which is 6586.64% down from last year.
  • As of Q3 2025, Phathom Pharmaceuticals' Non Operating Income stood at -$14.7 million, which was up 53.45% from -$15.9 million recorded in Q2 2025.
  • In the past 5 years, Phathom Pharmaceuticals' Non Operating Income registered a high of -$2.8 million during Q1 2022, and its lowest value of -$15.9 million during Q2 2025.
  • Its 4-year average for Non Operating Income is -$10.8 million, with a median of -$9.7 million in 2023.
  • Data for Phathom Pharmaceuticals' Non Operating Income shows a peak YoY increase of 1142.26% (in 2023) and a maximum YoY decrease of 18042.77% (in 2023) over the last 5 years.
  • Over the past 4 years, Phathom Pharmaceuticals' Non Operating Income (Quarter) stood at -$8.4 million in 2022, then fell by 15.35% to -$9.7 million in 2023, then tumbled by 55.07% to -$15.0 million in 2024, then increased by 2.21% to -$14.7 million in 2025.
  • Its last three reported values are -$14.7 million in Q3 2025, -$15.9 million for Q2 2025, and -$15.5 million during Q1 2025.